全球跨国制药巨头如美国礼莱正加足马力,大力扩张日本的销售业务,试图在这个全球第二大药物市场上获得更多的份额。日本近些年的药品法律管制有所松动,传统上日本药品市场由于难以掌握的法律规定和排外的市场策略而难以进入,现在则对各大制药公司极具吸引力。在近日一个关于大型跨国制药公司未来10年在日本市场份额如何稳定的研讨会上,礼莱日本公司总裁AndrewMascarenhas提出礼莱公司的目标是到2005年成为日本市场前25位的制药企业,到2010年跃居前10位。礼莱日本公司等国际药业巨头扩张日 Global pharmaceutical giant Rieys, such as the United States, is adding enough horsepower to expand its sales operations in Japan in an attempt to gain more share in the world’s second-largest drug market. In Japan, the legal control of pharmaceuticals has been somewhat loosened. Traditionally, the Japanese pharmaceutical market, which has been difficult to access because of the hard-to-grasp legal provisions and xenophobic marketing strategies, is now attractive to major pharmaceutical companies. In a recent seminar on how large multinational pharmaceutical companies are stabilizing their market share in Japan over the next 10 years, Andrew Lascar, president of Lilly Japan, proposed that Lilly Company’s goal was to become the top 25 pharmaceutical companies in the Japanese market by 2005 and 2010 Leap in the top ten years. Lilly Japanese companies and other international pharmaceutical giant expansion days